Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Diabetic Nephropathy | Current Treatment: Physician Insights | US | 2017

Login to access report north_east
Contact sales account_box

Diabetic nephropathy (DN) refers to kidney disease caused by diabetes. DN is a leading cause of chronic kidney disease (CKD), and is associated with high morbidity, mortality, and cost. Use of pharmacotherapy for DN varies by disease severity, physician specialty, and CKD stage. Physicians consider management of DN challenging because current therapies manage only the complications of DN. Currently available therapies have limited efficacy, are unable to treat the underlying disease, and prevent progressive renal decline in patients. Our Current Treatment deep dive content investigates the current prescribing practices for DN and focuses on the various factors driving the these treatment decisions.

Questions Answered

  • Do treatment decisions for DN differ based on disease progression and the specialty of the treating physician?
  • Which attributes are most important in choosing drugs for the management of DN patients?
  • How do physicians perceive standard of care therapies such as ACE inhibitors or ARBs for DN?
  • What is the level of satisfaction among physicians with currently available DN treatments? What is the level of familiarity and interest in products in the development pipeline?
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Major Depressive Disorder (DSM-V) – Current Treatment – Current Treatment: Physician Insights – Major Depressive Disorder (EU5)
Across the EU5, the treatment landscape for major depressive disorder (MDD) is shaped by the widespread use of SSRIs and SNRIs, which continue to serve as firstline therapy due to their…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east